Amolimogene

Identification

Name

Amolimogene

Accession Number

DB04904

Type

Biotech

Groups

Investigational

Description

Amolimogene is an investigational therapeutic designed to specifically augment the body's defensive response to human papillomavirus (HPV). Amolimogene was biologically engineered as a targeted therapy for the treatment of cervical dysplasia.

Pharmacology

Intended for the treatment of cervical dysplasia associated with the human papillomavirus (HPV).

Structured Indications

Not Available

Pharmacodynamics

Amolimogene was shown to be well tolerated in all patients and to promote the resolution of CIN 2/3 in women younger than 25 years.

Mechanism of action

Amolimogene particles are injected into the leg muscle and encounter cells known as antigen presenting cells, which play a pivotal role in activating the immune system. Once inside the dendritic cells, amolimogene dissolves and the genetic information that codes for parts of the HPV virus is released. The information is then processed, attaches to a protein and transported to the surface of the dendritic cell, attracting immune cells known as T cells. The T cells attach to the protein holding the information and begin to divide, creating many HPV targeted T cells. These cells migrate to the cervix where they encounter HPV expressing cells. Once inside the cervix, the T cells surround and eliminate the abnormal precancerous cells that cause cervical dysplasia. The result can be normal, healthy tissue.